C4 Therapeutics Inc
NASDAQ:CCCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
US |
|
C
|
Consolidated Edison Inc
F:EDC
|
US |
|
Societatea de Producere a Energiei Electrice in Hidrocentrale Hidroelectrica SA
F:E28
|
RO |
|
U
|
Union Pacific Corp
XMUN:UNP
|
US |
|
Grab Holdings Ltd
NASDAQ:GRAB
|
SG |
|
Microsoft Corp
NASDAQ:MSFT
|
US |
|
B
|
BioNTech SE
F:22UA
|
DE |
|
PubMatic Inc
NASDAQ:PUBM
|
US |
|
NN Group NV
AEX:NN
|
NL |
|
Rheinmetall AG
F:RHMB
|
DE |
|
Nutrien Ltd
TSX:NTR
|
CA |
Wall St Price Targets
CCCC Price Targets Summary
C4 Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CCCC is 12.53 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CCCC's stock price target?
Price Target
12.53
USD
According to Wall Street analysts, the average 1-year price target for
CCCC is 12.53 USD with a low forecast of 6.06 USD and a high forecast of 31.5 USD.
What is the Revenue forecast for C4 Therapeutics Inc?
Projected CAGR
45%
Over the last 6 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 8 years is 45%.